ArticleCancer diagnosis & prognosis
Immune Checkpoint Inhibitor Resistance in Rectal Adenocarcinoma Containing a Mismatch Repair Deficiency Component: A Case Report.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Immune checkpoint inhibitors (ICIs) are important therapeutic options for metastatic colorectal cancer showing microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR). We report a case of rectal adenocarcinoma with liver metastases diagnosed as dMMR cancer that was resistant to ICI therapy, leading us to conduct an additional pathological analysis to uncover the reasons underlying ICI resistance. Case Report: A 53-year-old woman had a tumor in the lower rectum. Biopsy revealed coexisting gland-forming low-grade (well-to-moderately differentiated) adenocarcinoma and high-grade (poorly differentiated) adenocarcinoma components arising in a background of tubulovillous adenoma. Immunohistochemically, MLH1 and MSH2 expression was lost in the high-grade adenocarcinoma component, but retained in the adenomatous and low-grade adenocarcinoma components. The patient was diagnosed as having cT4N2M1, stage IV disease (Union for International Cancer Control TNM Classification of Malignant Tumours), with multiple liver metastases. The tumor was unresectable, so treatment with ICIs, including pembrolizumab, was administered; however, no clinical response was observed, and the liver metastases progressed. Additional immunohistochemistry showed a high density of CD3-positive T lymphocytes in high-grade adenocarcinoma as compared with other components. Human leukocyte antigen (HLA)-A/B/C expression was observed in all tumor components, whereas HLA-DR expression differed. HLA-E was expressed in all tumor components, while heterogeneous HLA-G expression was detected in tumor cells. Conclusion: The findings of the present case suggest that ICI resistance might be due to the heterogeneity of dMMR. Thus, comprehensive pathological evaluation of tumor heterogeneity may be important for understanding ICI responsiveness in metastatic colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.